[go: up one dir, main page]

MX2015011713A - Compuestos para el tratamiento de cancer. - Google Patents

Compuestos para el tratamiento de cancer.

Info

Publication number
MX2015011713A
MX2015011713A MX2015011713A MX2015011713A MX2015011713A MX 2015011713 A MX2015011713 A MX 2015011713A MX 2015011713 A MX2015011713 A MX 2015011713A MX 2015011713 A MX2015011713 A MX 2015011713A MX 2015011713 A MX2015011713 A MX 2015011713A
Authority
MX
Mexico
Prior art keywords
compounds
cancer
cancer treatment
inhibitors
tubulin
Prior art date
Application number
MX2015011713A
Other languages
English (en)
Other versions
MX375059B (es
Inventor
Duane D Miller
Wei Li
Jin Wang
Jianjun Chen
Original Assignee
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation
Publication of MX2015011713A publication Critical patent/MX2015011713A/es
Publication of MX375059B publication Critical patent/MX375059B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas para tratar cáncer comprendiendo inhibidores BRAF (por ejemplo, vemurafenib) y/o inhibidores MEK, por ejemplo, trametinib, R05068760, en combinación con compuestos anti-tubulina de la invención u otros inhibidores de tubulina conocidos, y que usan tales composiciones para tratar cáncer, tal como melanoma, cáncer resistente a medicamento y metástasis de cáncer.
MX2015011713A 2013-03-05 2014-03-05 Compuestos para el tratamiento de cancer. MX375059B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
PCT/US2014/020858 WO2014138279A1 (en) 2013-03-05 2014-03-05 Compounds for treatment of cancer

Publications (2)

Publication Number Publication Date
MX2015011713A true MX2015011713A (es) 2016-05-09
MX375059B MX375059B (es) 2025-03-06

Family

ID=51491914

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011713A MX375059B (es) 2013-03-05 2014-03-05 Compuestos para el tratamiento de cancer.
MX2020009256A MX2020009256A (es) 2013-03-05 2015-09-04 Compuestos para el tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009256A MX2020009256A (es) 2013-03-05 2015-09-04 Compuestos para el tratamiento de cancer.

Country Status (11)

Country Link
US (2) US10022356B2 (es)
EP (1) EP2964028A4 (es)
JP (2) JP6835472B2 (es)
KR (1) KR102246652B1 (es)
CN (2) CN105163584B (es)
AU (2) AU2014225761B2 (es)
CA (1) CA2904338C (es)
IL (1) IL241232B (es)
MX (2) MX375059B (es)
RU (1) RU2708247C2 (es)
WO (1) WO2014138279A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
ES2927660T3 (es) * 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
EP3708164A1 (en) 2014-05-06 2020-09-16 Oncternal Therapeutics, Inc Compounds for treatment of cancer
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
WO2016106359A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
CA2987340C (en) * 2015-06-05 2024-04-02 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
AU2015401587A1 (en) * 2015-07-09 2018-02-01 The Jackson Laboratory Methods of treating cancer by administering a MEK inhibitor in combination with a proteasome inhibitor
CA2995586A1 (en) * 2015-08-06 2017-02-09 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
EP3429598A4 (en) 2016-03-16 2020-04-01 Dicerna Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH BETA-CATENIN
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
EP3594357A4 (en) * 2017-03-10 2020-03-11 Konica Minolta, Inc. METHOD FOR ESTIMATING THERAPEUTIC EFFECTIVENESS
JP7291399B2 (ja) 2017-05-03 2023-06-15 ティン セラピューティクス エルエルシー 難聴の予防および治療のための組成物および方法
WO2019099873A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
US20190374512A1 (en) * 2018-05-15 2019-12-12 University Of Tennessee Research Foundation Compounds for treatment of pancreatic cancer
MX2020012291A (es) * 2018-05-15 2021-03-25 Univ Tennessee Res Found Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
AU2019354771A1 (en) 2018-10-05 2021-04-01 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
MX2022009347A (es) * 2020-01-31 2022-12-15 Verastem Inc Terapia de combinacion para el tratamiento del crecimiento celular anormal.
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
WO2022006512A1 (en) * 2020-07-02 2022-01-06 The Board Of Regents Of The University Of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
WO2024036114A2 (en) * 2022-08-08 2024-02-15 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
DE69132006T2 (de) 1990-11-30 2000-08-03 Otsuka Pharmaceutical Co., Ltd. Thiazolederivate als inhibitoren von aktivem sauerstoff
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
CA2461363A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US7071218B2 (en) 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US20040192743A1 (en) 2003-02-12 2004-09-30 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
CA2522562C (en) 2003-04-17 2013-09-03 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004110357A2 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
CN1902184A (zh) 2003-11-18 2007-01-24 田纳西大学研究基金会 噻唑烷酮酰胺、噻唑烷羧酸酰胺、其制备方法及其用途
EP1692111A2 (en) 2003-12-12 2006-08-23 Wyeth, A Corporation of the State of Delaware Quinolines useful in treating cardiovascular disease
BRPI0508594A (pt) 2004-03-08 2007-08-21 Wyeth Corp moduladores de canal de ìon
CA2584493A1 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
MX2007016463A (es) * 2005-06-22 2008-03-04 Plexxikon Inc Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa.
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2652328A1 (en) * 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited Prophylactic and therapeutic agent for cancer
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
ES2927660T3 (es) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
KR101729116B1 (ko) * 2009-10-16 2017-05-02 노바르티스 아게 조 합 물
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US8426418B2 (en) * 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
WO2012131909A1 (ja) 2011-03-29 2012-10-04 三菱電機株式会社 サーボ制御装置の異常診断装置および異常診断システム
WO2012135753A1 (en) * 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and erlotinib, and methods of use
JP5906303B2 (ja) * 2011-04-07 2016-04-20 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としてのイミダゾピリダジン類
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
MX375059B (es) 2025-03-06
RU2708247C2 (ru) 2019-12-05
CA2904338A1 (en) 2014-09-12
KR102246652B1 (ko) 2021-04-29
AU2014225761A1 (en) 2015-10-08
AU2014225761B2 (en) 2018-06-07
WO2014138279A1 (en) 2014-09-12
MX2020009256A (es) 2020-10-28
CN109568312A (zh) 2019-04-05
KR20150123328A (ko) 2015-11-03
JP2016510748A (ja) 2016-04-11
EP2964028A1 (en) 2016-01-13
US20180325872A1 (en) 2018-11-15
US10022356B2 (en) 2018-07-17
US20160015688A1 (en) 2016-01-21
EP2964028A4 (en) 2017-06-07
RU2015142102A (ru) 2017-04-07
JP2019077727A (ja) 2019-05-23
IL241232B (en) 2021-02-28
AU2018226470B2 (en) 2019-11-28
IL241232A0 (en) 2015-11-30
RU2015142102A3 (es) 2018-03-13
CN105163584A (zh) 2015-12-16
CN105163584B (zh) 2019-06-04
AU2018226470A1 (en) 2018-09-27
US10525037B2 (en) 2020-01-07
CA2904338C (en) 2022-07-05
JP6835472B2 (ja) 2021-02-24

Similar Documents

Publication Publication Date Title
MX2015011713A (es) Compuestos para el tratamiento de cancer.
ZA201708692B (en) Antibacterial compounds
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015006478A (es) Inhibidores de glutaminasa y metodos de empleo.
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX394452B (es) Inhibicion de la actividad de olig2.
MX2016008304A (es) Usos de oligouronatos en el tratamiento de cancer.
BR112013019680A2 (pt) combinações compreendendo macitentana para o tratamento de glioblastoma multiforme
ZA201901367B (en) Inhibition of olig2 activity
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration